The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease
Abstract
Objective—: Interleukin (IL)-17A is regarded as an important cytokine to drive psoriasis, an inflammatory skin disease marked by increased cardiovascular mortality. We aimed to test the hypothesis that overproduction of IL-17A in the skin leading to dermal inflammation may systemically cause vascular dysfunction in psoriasis-like skin disease. Approach and Results—: Conditional overexpression of IL-17A in keratinocytes caused severe psoriasis-like skin inflammation in mice (K14-IL-17A ind/+ mice), associated with increased reactive oxygen species formation and circulating CD11b + inflammatory leukocytes in blood, with endothelial dysfunction, increased systolic blood pressure, left ventricular hypertrophy, and reduced survival compared with controls. In K14-IL-17A ind/+ mice, immunohistochemistry and flow cytometry revealed increased vascular production of the nitric oxide/superoxide reaction product peroxynitrite and infiltration of the vasculature with myeloperoxidase + CD11b + GR1 + F4/80 − cells accompanied by increased expression of the inducible nitric oxide synthase and the nicotinamide dinucleotide phosphate (NADPH) oxidase, nox2. Neutrophil depletion by anti-GR-1 antibody injections reduced oxidative stress in blood and vessels. Neutralization of tumor necrosis factor-α and IL-6 (both downstream of IL-17A) reduced skin lesions, attenuated oxidative stress in heart and blood, and partially improved endothelial dysfunction in K14-IL-17A ind/+ mice. Conclusions—: Dermal overexpression of IL-17A induces systemic endothelial dysfunction, vascular oxidative stress, arterial hypertension, and increases mortality mainly driven by myeloperoxidase + CD11b + GR1 + F4/80 − inflammatory cells. Depletion of the GR-1 + immune cells or neutralization of IL-17A downstream cytokines by biologicals attenuates the vascular phenotype in K14-IL-17A ind/+ mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Rajagopalan, S., Kurz, S., Münzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K., & Harrison, D. G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118623 · Cited by 2,449
Self-citationInterleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.59 · Cited by 1,129
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice
Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S., & Albina, J. E. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0407247 · Cited by 1,046
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Inflammation, Immunity, and Hypertension
Harrison, D. G., Guzik, T. J., Lob, H. E., Madhur, M. S., Marvar, P. J., Thabet, S. R., Vinh, A., & Weyand, C. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.163576 · Cited by 871
Interleukin 17 Promotes Angiotensin II–Induced Hypertension and Vascular Dysfunction
Madhur, M. S., Lob, H. E., McCann, L. A., Iwakura, Y., Blinder, Y., Guzik, T. J., & Harrison, D. G. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.145094 · Cited by 827
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation
Kaplanski, G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00013-3 · Cited by 811
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.273 · Cited by 805
Mehta, N. N., Azfar, R. S., Shin, D. B., Neimann, A. L., Troxel, A. B., & Gelfand, J. M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp567 · Cited by 706
Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase
Eiserich, J. P., Baldus, S., Brennan, M.-L., Ma, W., Zhang, C., Tousson, A., Castro, L., Lusis, A. J., Nauseef, W. M., White, C. R., et al. (2002) · Science · doi:10.1126/science.1106830 · Cited by 685
Hürlimann, D., Forster, A., Noll, G., Enseleit, F., Chenevard, R., Distler, O., Béchir, M., Spieker, L. E., Neidhart, M., Michel, B. A., et al. (2002) · Circulation · doi:10.1161/01.cir.0000037521.71373.44 · Cited by 574
Teunissen, M. B. M., Bos, J. D., Koomen, C. W., de Waal Malefyt, R., & Wierenga, E. A. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00347.x · Cited by 570
The Risk of Mortality in Patients With Psoriasis: Results From a Population-Based Study
Gelfand, J. M., Troxel, A. B., Lewis, J. D., Kurd, S. K., Shin, D. B., Wang, X., Margolis, D. J., & Strom, B. L. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.12.1493 · Cited by 533
Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis
Chandran, V., & Raychaudhuri, S. P. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.12.001 · Cited by 510
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Wenzel, P., Knorr, M., Kossmann, S., Stratmann, J., Hausding, M., Schuhmacher, S., Karbach, S. H., Schwenk, M., Yogev, N., Schulz, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.034470 · Cited by 504
Self-citationLoss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis
Taleb, S., Romain, M., Ramkhelawon, B., Uyttenhove, C., Pasterkamp, G., Herbin, O., Esposito, B., Perez, N., Yasukawa, H., Van Snick, J., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090545 · Cited by 408
IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice
Haak, S., Croxford, A. L., Kreymborg, K., Heppner, F. L., Pouly, S., Becher, B., & Waisman, A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35997 · Cited by 399
Self-citationPathophysiology, diagnosis and prognostic implications of endothelial dysfunction
Münzel, T., Sinning, C., Post, F., Warnholtz, A., & Schulz, E. (2008) · Annals of Medicine · doi:10.1080/07853890701854702 · Cited by 396
Self-citationPRODANOWICH, S., MA, F., TAYLOR, J., PEZON, C., FASIHI, T., & KIRSNER, R. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.06.017 · Cited by 384
Inhibition of IL-17A Attenuates Atherosclerotic Lesion Development in ApoE-Deficient Mice
Erbel, C., Chen, L., Bea, F., Wangler, S., Celik, S., Lasitschka, F., Wang, Y., Böckler, D., Katus, H. A., & Dengler, T. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901126 · Cited by 358
Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events
Mehta, N. N., Yu, Y., Pinnelas, R., Krishnamoorthy, P., Shin, D. B., Troxel, A. B., & Gelfand, J. M. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.03.028 · Cited by 345
Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension
Nguyen, H., Chiasson, V. L., Chatterjee, P., Kopriva, S. E., Young, K. J., & Mitchell, B. M. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvs422 · Cited by 300
Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1211 · Cited by 289
Oelze, M., Mollnau, H., Hoffmann, N., Warnholtz, A., Bodenschatz, M., Smolenski, A., Walter, U., Skatchkov, M., Meinertz, T., & Münzel, T. (2000) · Circulation Research · doi:10.1161/01.res.87.11.999 · Cited by 253
Self-citationMehta, N. N. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.119 · Cited by 223
Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis
Balci, D., Balci, A., Karazincir, S., Ucar, E., Iyigun, U., Yalcin, F., Seyfeli, E., Inandi, T., & Egilmez, E. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02936.x · Cited by 203
Gisterå, A., Robertson, A.-K. L., Andersson, J., Ketelhuth, D. F. J., Ovchinnikova, O., Nilsson, S. K., Lundberg, A. M., Li, M. O., Flavell, R. A., & Hansson, G. K. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006133 · Cited by 194
El Malki, K., Karbach, S. H., Huppert, J., Zayoud, M., Reißig, S., Schüler, R., Nikolaev, A., Karram, K., Münzel, T., Kuhlmann, C. R. W., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.318 · Cited by 174
Self-citationNeutrophil-Derived Cathelicidin Promotes Adhesion of Classical Monocytes
Wantha, S., Alard, J.-É., Megens, R. T. A., van der Does, A. M., Döring, Y., Drechsler, M. D., Pham, C. T. N., Wang, M., Wang, J.-M., Gallo, R. L., et al. (2013) · Circulation Research · doi:10.1161/circresaha.112.300666 · Cited by 155
Dowlatshahi, E. A., Kavousi, M., Nijsten, T. E. C., Ikram, M. A., Albert Hofman, D., Franco, O. H., & Wakkee, M. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.131 · Cited by 131
IL-6 Regulates Neutrophil Microabscess Formation in IL-17A-Driven Psoriasiform Lesions
Croxford, A. L., Karbach, S. H., Kurschus, F. C., Wörtge, S., Nikolaev, A., Yogev, N., Klebow, S., Schüler, R., Reißig, S., Piotrowski, C., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.404 · Cited by 123
Self-citationPsoriasis and cardiovascular disease
Vena, G. A., Vestita, M. G., & Cassano, N. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01308.x · Cited by 107
Roller, A., Perino, A., Dapavo, P., Soro, E., Okkenhaug, K., Hirsch, E., & Ji, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103173 · Cited by 85
Gisterå, A., Robertson, A.-K., Andersson, J., Ketelhuth, D. F. J., Овчинникова, О. А., Nilsson, S. K., Lundberg, A. M., Li, M. O., Flavell, R. A., & Hansson, G. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.233 · Cited by 78
Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis
Miller, I. M., Skaaby, T., Ellervik, C., & Jemec, G. B. E. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12490 · Cited by 69
Wild, P. S., Sinning, C., Roth, A. L., Wilde, S., Schnabel, R. B., Lubos, E., Zeller, T., Keller, T., Lackner, K. J., Blettner, M., et al. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.911933 · Cited by 68
Self-citationPsoriasis and atherosclerosis: two plaques, one syndrome?
Flammer, A. J., & Ruschitzka, F. T. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr425 · Cited by 58
To Be 17 Again — Anti–Interleukin-17 Treatment for Psoriasis
Waisman, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1201071 · Cited by 41
Self-citationRisk and predictors of cardiovascular disease in psoriasis: a population‐based study
Kremers, H. M., Dierkhising, R., Crowson, C. S., Icen, M., Ernste, F. C., & McEvoy, M. T. (2012) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2011.05430.x · Cited by 37
Wu, J. J., Poon, K. T., & Bebchuk, J. D. (2013) · PubMed · Cited by 35
Cited by
Psoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.064 · Cited by 1,145
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“To judge from studies in mice, the dysfunction is likely due to upregulation of NOX with increased ROS production causing a decreased NO bioavailability, and results from the NFjB induction by cytokines (Lesniewski et al. 2011, Karbach et al. 2014).”
BackgroundThe Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Enthesitis: from pathophysiology to treatment
Schett, G., Lories, R. J., D'Agostino, M.-A., Elewaut, D., Kirkham, B., Soriano, E. R., & McGonagle, D. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.188 · Cited by 503
Targeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501
“More recently our group provided insight into the mechanisms of vascular dysfunction caused by inflammation of the skin in an experimental model of psoriasis (Karbach et al., 2014b).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Karbach, S., Croxford, A. L., Oelze, M., Schüler, R., Minwegen, D., Wegner, J., Koukes, L., Yogev, N., Nikolaev, A., Reißig, S., Ullmann, A., Knorr, M., Waldner, M., Neurath, M. F., Li, H., Wu, Z., Brochhausen, C., Scheller, J., Rose-John, S., Piotrowski, C., Bechmann, I., Radsak, M., Wild, P., Daiber, A., von Stebut, E., Wenzel, P., Waisman, A., & Münzel, T.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2014-12
- Volume
- 34
- Issue
- 12
- Pages
- 2658-2668
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2004659474
- Cited by
- 261
- References
- 49
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.